Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

B Escudier; M D Michaelson; R J Motzer; T E Hutson; J I Clark; H Y Lim; E Porfiri; P Zalewski; G Kannourakis; M Staehler; J Tarazi; B Rosbrook; L Cisar; S Hariharan; S Kim; B I Rini

首页> 外文期刊>British Journal of Cancer >Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

【24h】

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

机译：阿昔替尼与索拉非尼在晚期肾细胞癌中的作用：一项随机III期临床试验先前治疗的亚分析

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background:In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.

机译：背景：在AXIS试验中，阿昔替尼与索拉非尼相比先前用舒尼替尼或细胞因子治疗的晚期肾细胞癌（RCC）患者延长了无进展生存期（PFS）。

著录项

来源
《British Journal of Cancer》 |2014年第12期|共8页
作者
B Escudier; M D Michaelson; R J Motzer; T E Hutson; J I Clark; H Y Lim; E Porfiri; P Zalewski; G Kannourakis; M Staehler; J Tarazi; B Rosbrook; L Cisar; S Hariharan; S Kim; B I Rini;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial [J] . MotzerR.J., EscudierB., TomczakP., The lancet oncology . 2013,第6期

机译：阿昔替尼vs索拉非尼作为晚期肾细胞癌的二线治疗：总体生存分析和一项随机3期试验的更新结果
2. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial [J] . KenneyP.A., WoodC.G. European urology . 2012,第1期

机译：回复：阿西替尼与索拉非尼在晚期肾细胞癌（AXIS）中的比较有效性：一项随机的3期临床试验
3. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. [J] . Rini BI, Escudier B, Tomczak P, The Lancet . 2011,第9807期

机译：阿西替尼与索拉非尼在晚期肾细胞癌（AXIS）中的比较有效性：一项随机的3期临床试验。
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Tumor Infiltrating Lymphocyte Therapy for Renal Cell Carcinoma: Methods for ex vivo Expansion and T-Cell Memory Induction [D] . Braun, Mitchell W. 2021

机译：肾细胞癌患者肿瘤浸润淋巴细胞治疗：用于脱型膨胀和T细胞记忆诱导的方法
6. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [O] . B Escudier, M D Michaelson, R J Motzer, 2014

机译：阿昔替尼与索拉非尼在晚期肾细胞癌中的作用：一项随机III期临床试验先前治疗的亚分析
7. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [O] . B Escudier, M D Michaelson, R J Motzer, 2014

机译：Axitinib与索拉非尼在晚期肾细胞癌中：来自随机阶段III试验的先前治疗的subanalyses

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅